Palliative care and coping in patients with acute myeloid leukemia: Mediation analysis of data from a randomized clinical trial.
acute myeloid leukemia (AML)
coping
distress
palliative care intervention
quality of life
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 12 2021
15 12 2021
Historique:
revised:
06
08
2021
received:
02
06
2021
accepted:
09
08
2021
pubmed:
31
8
2021
medline:
11
3
2022
entrez:
30
8
2021
Statut:
ppublish
Résumé
It has been shown previously that integrated palliative care for patients with acute myeloid leukemia (AML) during intensive chemotherapy leads to improvements in quality of life (QOL) and mood. Coping has been shown to mediate palliative care interventions in advanced cancer; the mechanisms by which improvements occur among patients with AML remain unexplained. The authors conducted a secondary analysis of data from a multisite randomized trial of integrated palliative and oncology care (IPC; n = 86) versus usual care (n = 74) for hospitalized patients with AML undergoing intensive chemotherapy. IPC patients met with palliative care at least twice weekly during their initial and subsequent hospitalizations. Patients completed the Functional Assessment of Cancer Therapy-Leukemia, the Hospital Anxiety and Depression Scale, and the Brief Coping Orientation to Problems Experienced Inventory to assess QOL, mood, and coping at the baseline and at weeks 2, 4, 12, and 24. Linear regression models were used to assess the effect of IPC on coping. Causal mediation regression models were used to examine whether changes in coping mediated intervention effects on patient-reported outcomes at week 2. One hundred sixty eligible patients (68.1%) were enrolled. Those randomized to IPC reported improvements in approach-oriented coping (P < .01) and reductions in avoidant coping (P < .05). These changes in coping mediated the intervention effects on QOL (95% CI, 2.14-13.63), depression (95% CI, -2.05 to -0.27), and anxiety symptoms (95% CI, -1.25 to -0.04). Changes in approach-oriented and avoidant coping accounted for 78% of the total palliative care intervention effect on QOL, for 66% of the effect on depression, and for 35% of the effect on anxiety symptoms. Palliative care integrated during intensive chemotherapy for patients with AML facilitates coping strategy use. Improvement in coping skills accounts for a substantial proportion of the effect from a palliative care intervention on patient-reported outcomes.
Sections du résumé
BACKGROUND
It has been shown previously that integrated palliative care for patients with acute myeloid leukemia (AML) during intensive chemotherapy leads to improvements in quality of life (QOL) and mood. Coping has been shown to mediate palliative care interventions in advanced cancer; the mechanisms by which improvements occur among patients with AML remain unexplained.
METHODS
The authors conducted a secondary analysis of data from a multisite randomized trial of integrated palliative and oncology care (IPC; n = 86) versus usual care (n = 74) for hospitalized patients with AML undergoing intensive chemotherapy. IPC patients met with palliative care at least twice weekly during their initial and subsequent hospitalizations. Patients completed the Functional Assessment of Cancer Therapy-Leukemia, the Hospital Anxiety and Depression Scale, and the Brief Coping Orientation to Problems Experienced Inventory to assess QOL, mood, and coping at the baseline and at weeks 2, 4, 12, and 24. Linear regression models were used to assess the effect of IPC on coping. Causal mediation regression models were used to examine whether changes in coping mediated intervention effects on patient-reported outcomes at week 2.
RESULTS
One hundred sixty eligible patients (68.1%) were enrolled. Those randomized to IPC reported improvements in approach-oriented coping (P < .01) and reductions in avoidant coping (P < .05). These changes in coping mediated the intervention effects on QOL (95% CI, 2.14-13.63), depression (95% CI, -2.05 to -0.27), and anxiety symptoms (95% CI, -1.25 to -0.04). Changes in approach-oriented and avoidant coping accounted for 78% of the total palliative care intervention effect on QOL, for 66% of the effect on depression, and for 35% of the effect on anxiety symptoms.
CONCLUSIONS
Palliative care integrated during intensive chemotherapy for patients with AML facilitates coping strategy use. Improvement in coping skills accounts for a substantial proportion of the effect from a palliative care intervention on patient-reported outcomes.
Identifiants
pubmed: 34460937
doi: 10.1002/cncr.33886
pmc: PMC8664993
mid: NIHMS1733306
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4702-4710Subventions
Organisme : NCI NIH HHS
ID : K08 CA251654
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA092203
Pays : United States
Informations de copyright
© 2021 American Cancer Society.
Références
JAMA Oncol. 2021 Feb 1;7(2):238-245
pubmed: 33331857
J Clin Oncol. 2010 Feb 1;28(4):586-95
pubmed: 20038732
Curr Hematol Malig Rep. 2017 Aug;12(4):300-308
pubmed: 28639084
J Clin Oncol. 2018 Jan 1;36(1):53-60
pubmed: 29140772
Ther Adv Hematol. 2020 Mar 18;11:2040620720913010
pubmed: 32215195
J Pers Soc Psychol. 1989 Feb;56(2):267-83
pubmed: 2926629
Psychooncology. 1999 Jan-Feb;8(1):64-73
pubmed: 10202784
J Clin Oncol. 2020 Mar 20;38(9):944-953
pubmed: 32023164
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Blood Rev. 2020 Nov;44:100679
pubmed: 32249005
Leukemia. 2007 Apr;21(4):845-8
pubmed: 17287855
Curr Opin Support Palliat Care. 2018 Dec;12(4):530-537
pubmed: 30379755
Psychooncology. 2013 Feb;22(2):299-307
pubmed: 22081505
J Am Geriatr Soc. 2016 Oct;64(10):1988-1995
pubmed: 27627675
Oncol Nurs Forum. 2015 Mar;42(2):E91-E101
pubmed: 25806895
J Pain Symptom Manage. 2017 Jan;53(1):131-138
pubmed: 27725249
J Consult Clin Psychol. 2013 Apr;81(2):318-35
pubmed: 22663900
J Clin Oncol. 2017 Aug 1;35(22):2551-2557
pubmed: 28574777
Int J Behav Med. 1997;4(1):92-100
pubmed: 16250744
Chron Respir Dis. 2013 Feb;10(1):35-47
pubmed: 23355404
Value Health. 2012 Dec;15(8):1051-8
pubmed: 23244807
J Clin Oncol. 2018 Apr 10;36(11):1096-1102
pubmed: 29474102
Crit Rev Oncol Hematol. 2007 Oct;64(1):19-30
pubmed: 17765568
J Hematol Oncol. 2021 Mar 23;14(1):49
pubmed: 33757574
J Oncol Pract. 2015 Mar;11(2):e230-8
pubmed: 25784580
J Clin Oncol. 2020 Oct 20;38(30):3506-3517
pubmed: 32687450
JAMA. 2016 Nov 22;316(20):2094-2103
pubmed: 27893130
Leukemia. 2019 Oct;33(10):2393-2402
pubmed: 30923318
Psychooncology. 2017 Dec;26(12):2063-2068
pubmed: 27862591
Cancer. 2016 Jul 1;122(13):2110-6
pubmed: 27089045
Leuk Res. 2013 Jul;37(7):731-6
pubmed: 23490030
Curr Hematol Malig Rep. 2019 Dec;14(6):523-535
pubmed: 31776773